Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
8th grade Good
|
Filing tables
Filing exhibits
- 10-K Annual report
- 10.40 Amendment Agreement Among Salix Pharmaceuticals, Inc and DR. Falk Pharma GMBH
- 10.41 License Agreement Between Aaipharma LLC, Aaipharma Inc and Salix Pharmaceuticals
- 10.42 Modification to Commercial Promissory Note Agreement
- 23.1 Consent of Independent Auditors
- 31.1 Certification by the CEO Pursuant to Section 240
- 31.2 Certification by the CFO Pursuant to Section 240
- 32.1 Certification by the CEO Pursuant to 18 Usc 1350
- 32.2 Certification by the CEO Pursuant to 18 Usc 1350
Salix Pharmaceuticals similar filings
Filing view
External links
Exhibit 23.1
Consent of Independent Auditors
We consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-110942) and on Form S-8 (Nos. 333-96771, 333-41801, 333-63604, 333-61497 and 333-47586) of Salix Pharmaceuticals, Ltd., of our report dated February 3, 2004, with respect to the consolidated financial statements and schedule of Salix Pharmaceuticals, Ltd. included in the Annual Report (Form 10-K) for the year ended December 31, 2003.
/s/ Ernst & Young LLP
Raleigh, North Carolina
March 12, 2004